Frontier Investment Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Frontier Investment Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$611K	Hold	3,917	–	–	0.04%	140
2020 Q1	$565K	Hold	3,917	–	–	0.04%	128
2019 Q4	$801K	Hold	3,917	–	–	0.05%	138
2019 Q3	$314K	Hold	3,917	–	–	0.02%	200
2019 Q2	$370K	Hold	3,917	–	–	0.02%	170
2019 Q1	$335K	Hold	3,917	–	–	0.02%	193
2018 Q4	$220K	Hold	3,917	–	–	0.02%	220
2018 Q3	$320K	Buy	+3,917	New	+$276K	0.02%	201

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Frontier Investment Management's RETA Position: Q2 2020 in Review

Frontier Investment Management held its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) position steady in Q2 2020 at 3,917 shares worth $611K. The position accounts for 0.04% of the portfolio, ranked #140.

Frontier Investment Management first reported a position in RETA in Q3 2018 and has held it in 8 quarters since. The position peaked at $801K in Q4 2019. 207 funds tracked by Wall St. Rank hold RETA as of Q2 2020.

Frontier Investment Management held 3,917 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $611K as of Q2 2020.
Frontier Investment Management left its Reata Pharmaceuticals, Inc. Class A Common Stock share count unchanged in Q2 2020.
Reata Pharmaceuticals, Inc. Class A Common Stock made up 0.04% of Frontier Investment Management's portfolio in Q2 2020, its #140 holding.
Frontier Investment Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and has held it in 8 quarters since.
Frontier Investment Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $801K in Q4 2019.
207 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2020.

Based on Frontier Investment Management's 13F filing for Q2 2020, filed 11 Aug 2020.